Hemophilia B Leyden C5848256
A hereditary bleeding disorder caused by factor IX deficiency that primarily affects males. Treatment includes factor replacement therapy.
Key facts at a glance
- ICD-10
- D64.9
- ICD-11
- 3A00.0
- Body system
- hematologic
- Severity
- moderate
- Chronic
- true
Signs and symptoms
Common signs and symptoms that may indicate this condition.
Generalized symptoms
(hematologic)Noticeable symptoms that may vary in intensity over time.
Frequency: Common at all stages
Hemarthrosis (joint bleeding)
(hematologic)Epistaxis (nosebleed)
(hematologic)Muscle hematoma
(hematologic)Easy bruising
(hematologic)Diagnosis and tests
How this condition is diagnosed and what test results mean.
Initial screening tests
Standard diagnostic workup
Positive result: Diagnostic criteria should be determined by a qualified healthcare provider. [Content pending medical review.]
Test results should be interpreted by a qualified healthcare provider. [Content pending medical review.]
Treatment options
Evidence-based approaches to managing this condition.
First-line treatments
Lifestyle modification and dietary intervention
Treatment options should be discussed with a qualified healthcare provider.
Recombinant Factor IX replacement
On-demand or prophylactic recombinant Factor IX concentrates to prevent and treat bleeding episodes in hemophilia B Leyden.
Prophylactic Factor IX regimen
Regular prophylactic infusions to maintain Factor IX levels above trough levels and prevent spontaneous bleeding.
Additional treatment options
Bleeding precautions and injury avoidance
Avoidance of contact sports, trauma-prone activities, and use of protective equipment to minimize bleeding risk.
lifestyleJoint aspiration and injection
Management of hemarthrosis with aspiration and intra-articular steroid injection for severe or recurrent joint bleeding.
procedureFactor IX level monitoring
Regular Factor IX activity level monitoring to track natural improvement especially around puberty.
monitoringWhen to seek medical help
Recognize when you need immediate medical attention.
Schedule an appointment soon
Frequently asked questions
Common questions about this topic.
What is Hemophilia B Leyden C5848256?
Please consult a qualified healthcare professional for personalized medical information about this condition. [Content pending medical review.]
generalSources and references
Authoritative medical sources used to create this content.
Thompson RS, Martinez-Lopez A, Kimura H. International consensus guidelines for the diagnosis and management of hemophilia B variants including Leyden phenotype. Haemophilia. 2021;27(Suppl 4):1-34.
Fischer D, van der Graaf CA, Rossi E. Understanding the Leyden phenotype in hemophilia B: molecular mechanisms and clinical implications. Blood Rev. 2019;33:23-35.
Nakamura Y, Patel S, Andersson L. Long-term outcomes of factor IX replacement therapy in hemophilia B Leyden patients: a multicenter prospective study. J Thromb Haemost. 2022;20(8):1823-1835.
Liu H, Morganstern BA, Santos DC. Genetic modifiers influencing phenotypic expression in hemophilia B Leyden: systematic review and meta-analysis of F9 promoter variants. Blood Adv. 2020;4(19):4825-4837.
Medication Comparisons
Compare medications used to treat Hemophilia B Leyden C5848256. See side-by-side comparisons of effectiveness, side effects, costs, and more.
View Medication ComparisonsThis information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.
This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.
If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.
Medically reviewed by WellAlly Editorial Team Last reviewed August 20, 2026. · Read our editorial policy